关键信息
-
基因名
ITGBL1
- 应用
-
别名
Osteoblast-specific cysteine-rich protein （Ten integrin EGF-like repeat domain-containing protein）
-
种属
Human
-
表达系统
HEK293
-
标签
N- His & C- Myc
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
O95965
-
表达区间
24-494aa
-
分子量
56.5 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
ITGBL1, or Integrin Beta-Like Protein 1, is a member of the integrin family, which plays a crucial role in mediating cellular adhesion and communication within the extracellular matrix. Research into ITGBL1 has gained attention due to its potential involvement in various physiological and pathological processes, such as cell migration, differentiation, and tissue remodeling. Studies have indicated that ITGBL1 may be implicated in cancer progression, inflammation, and fibrosis, suggesting that it could serve as a biomarker for certain diseases or as a therapeutic target. The recombinant production of ITGBL1 protein allows for detailed analysis of its structure and function, facilitating the exploration of its role in cell signaling pathways and interactions with other proteins. Moreover, the ability to produce ITGBL1 in a laboratory setting opens avenues for developing novel therapeutic strategies and diagnostic tools. Understanding the mechanisms by which ITGBL1 influences cellular behavior could provide insights into its potential as a target for interventions in diseases where integrin signaling is dysregulated. Overall, ongoing research into ITGBL1 and its recombinant variants holds promise not only for advancing our knowledge of cellular dynamics but also for developing targeted treatments for conditions linked to integrin-mediated pathways.
